Organon Past Earnings Performance
Past criteria checks 4/6
Organon's earnings have been declining at an average annual rate of -38.1%, while the Pharmaceuticals industry saw earnings growing at 8.4% annually. Revenues have been declining at an average rate of 0.5% per year. Organon's return on equity is 2181.3%, and it has net margins of 16.5%.
Key information
-38.1%
Earnings growth rate
-38.3%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | -0.5% |
| Return on equity | 2,181.3% |
| Net Margin | 16.5% |
| Next Earnings Update | 06 Aug 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Organon makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 6,347 | 1,047 | 1,887 | 511 |
| 31 Dec 23 | 6,263 | 1,023 | 1,891 | 528 |
| 30 Sep 23 | 6,150 | 585 | 1,892 | 536 |
| 30 Jun 23 | 6,168 | 754 | 1,794 | 526 |
| 31 Mar 23 | 6,145 | 746 | 1,766 | 504 |
| 31 Dec 22 | 6,174 | 917 | 1,702 | 471 |
| 30 Sep 22 | 6,292 | 1,011 | 1,717 | 439 |
| 30 Jun 22 | 6,355 | 1,107 | 1,665 | 398 |
| 31 Mar 22 | 6,365 | 1,304 | 1,658 | 368 |
| 31 Dec 21 | 6,304 | 1,351 | 1,669 | 339 |
| 30 Sep 21 | 6,314 | 1,525 | 1,620 | 289 |
| 30 Jun 21 | 6,327 | 1,762 | 1,553 | 257 |
| 31 Mar 21 | 6,258 | 1,917 | 1,421 | 232 |
| 31 Dec 20 | 6,532 | 2,256 | 1,356 | 210 |
| 31 Dec 19 | 7,777 | 3,306 | 1,443 | 220 |
| 31 Dec 18 | 9,777 | 2,153 | 1,956 | 365 |
| 31 Dec 17 | 10,500 | 1,801 | 2,250 | 355 |
Quality Earnings: 7XP has high quality earnings.
Growing Profit Margin: 7XP's current net profit margins (16.5%) are higher than last year (12.1%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 7XP's earnings have declined by 38.1% per year over the past 5 years.
Accelerating Growth: 7XP's earnings growth over the past year (40.3%) exceeds its 5-year average (-38.1% per year).
Earnings vs Industry: 7XP earnings growth over the past year (40.3%) exceeded the Pharmaceuticals industry 1.5%.
Return on Equity
High ROE: Whilst 7XP's Return on Equity (2181.25%) is outstanding, this metric is skewed due to their high level of debt.